Searched for
PHARMEASY LOAN REPAYMENT
Wondering how to succeed and build wealth? Rs 5,000 crore man shares his secret to true successA Bengaluru resident shared concerns about financial instability despite a high income. Dr. A Velumani, founder of Thyrocare, responded emp...- Ranjan Pai cuts Rs 1,400 crore cheque for Davidson Kempner debt, books Aakash seatsIn May, Byju’s had signed a Rs 2,000-crore ($240 million) structured credit deal with Davidson Kempner against the cash flows of Aakash Ins...
- Manipal group's Ranjan Pai likely to invest $250-300 million in Byju's subsidiary Aakash InstituteThe initial $170 million tranche will pay off Davidson Kempner debt; the Manipal chairman may rope in more PEs.
- Goldman may convert part-debt into equity in PharmEasyThe online pharmacy is also in talks to restructure debt terms ahead of rights issue; share sale set to open on September 4
- Goldman may part-convert Pharmeasy debt to equity; P2P lenders look to diversify partnershipsGoldman Sachs is likely to convert some of its loan to online pharmacy PharmEasy into equity. Buoyed by binding commitments from existing i...
- Tata-assembled iPhones coming up; Down rounds for Indian startups here to stay?The Tata Group is set to become the first Indian company to assemble Apple’s iPhone. The conglomerate is close to a deal to acquire Apple s...
- ETtech Explainer: What are down rounds and will they become the norm for Indian startups?A down round is when a privately held firm raises funds at a valuation lower than that ascribed in the previous round.
- PharmEasy valuation crash may not hit Thyrocare founder Velumani’s stakePharmEasy is faced with a steep cut in its valuation, with the new funding round pegging its shares at Rs 5 each compared to the Rs 50 per ...
- Till debt do us part: will startups go the PharmEasy way, and other top tech & startup stories this weekThis week’s ETtech newsbreak on PharmEasy going for a rights issue at a price 90% lower than its peak valuation of $5.6 billion to repay de...
- Exclusive: PharmEasy plans Rs 2,400-crore rights issue at 90% discount to repay loanMumbai-based epharmacy platform PharmEasy is likely to be valued at $500-600 million compared to the $5.6 billion valuation in 2021
- PharmEasy SOS: plans rights issue at 90% discount to repay loan; Cabinet approves Digital Personal Data billThe online drugstore plans to swallow a bitter pill in the hope that it can heal itself. The distress rights issue, if it goes through, wil...
- PharmEasy plans rights issue at 90% valuation cut; Amazon set to hit $8B India exportsEarlier in the day we broke the news that PharmEasy’s investors have taken control of the company as they plan a Rs 2,400 crore rights issu...
- What is really happening with digital credit in India, and other top stories this weekThe aftermath of Covid-19 and the subsequent moratorium on loan repayments burnt a massive hole in the loan books of lenders. While the lar...
- Scoop: PharmEasy valuation halved to $2.8 billion, logs ebitda profitability; Paytm’s loan biz decodedOnline pharmacy PharmEasy recorded a positive ebitda of around Rs 14 crore, which means it is operationally profitable, even as one of its ...
- Exclusive | Not selling Thyrocare, will cut cash burn: PharmEasy founders to boardPharmEasy’s parent API Holdings has also delayed internal plans for a potential initial public offering (IPO) to 2025, the people privy to ...
- 2022 Year in Review: the biggest stories in technology & startups this yearFrom controversies and regulatory diktats to high-profile exits and en masse layoffs, 2022 was a turbulent year for the tech industry.
- Musk offers to buy Twitter at original deal price; PayU-BillDesk flop to roil Indian fintechMusk began showing signs of buyer’s remorse shortly after the deal was announced, alleging that Twitter had misled him about the size of it...
- PharmEasy delays IPO, targets Ebitda breakeven by next yearThe Mumbai-based firm is also stitching up a private financing round through a rights issue where company founders are expected to invest p...
- Watch out for these factors in Thyrocare as closely as you would watch any symptoms!Through strategic acquisitions in the healthcare space, the company seems to be aiming to create “a holistic healthcare ecosystem”. From th...
- Raining unicornsIn today's ETtech Morning Dispatch newsletter: Pharmeasy and Cred are the newest entrants of India's startup unicorn club, BPM firms see hi...
Load More
